vTv Therapeutics Inc.
$37.75
▲
1.58%
2026-04-21 10:12:00
vtvtherapeutics.com
NCM: VTVT
Explore vTv Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$157.78 M
Current Price
$37.75
52W High / Low
$44 / $14
Stock P/E
—
Book Value
$5.19
Dividend Yield
—
ROCE
-39.41%
ROE
-78.94%
Face Value
—
EPS
$-3.2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
26
Beta
0.4
Debt / Equity
0
Current Ratio
13.54
Quick Ratio
13.54
Forward P/E
-9.82
Price / Sales
—
Enterprise Value
$364.75 M
EV / EBITDA
-11.12
EV / Revenue
—
Rating
Strong Buy
Target Price
$53.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | GH Research PLC | $21.5 | — | $1.33 B | — | -21.68% | -21.04% | $24.66 / $8.66 | $4.51 |
| 2. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
| 3. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 4. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 5. | Nutriband Inc. | $4.2 | — | $51.13 M | — | -103.12% | -1.36% | $11.68 / $3.42 | $0.62 |
| 6. | Aptorum Group Limited | $0.9 | — | $7.21 M | — | -12.89% | -10.79% | $4.47 / $0.65 | $2.84 |
| 7. | Xenetic Biosciences, Inc. | $3.4 | — | $7.09 M | — | -38.33% | -40% | $13.93 / $1.9 | $3.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0.02 M | — |
| Operating Profit | -7.88 M | -10.7 M | -7.72 M | -6.5 M | -4.89 M | — |
| Net Profit | -7.14 M | -8.7 M | -6.05 M | -5.09 M | -3.63 M | — |
| EPS in Rs | -1.81 | -2.21 | -1.54 | -1.29 | -0.92 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 1.02 M | 0 M | 2.02 M |
| Operating Profit | -32.81 M | -24.18 M | -25.5 M | -22.54 M |
| Net Profit | -26.97 M | -18.46 M | -20.25 M | -19.16 M |
| EPS in Rs | -6.85 | -4.69 | -5.14 | -4.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 89.9 M | 38.27 M | 11.02 M | 33.24 M |
| Total Liabilities | 25.46 M | 23.96 M | 29.57 M | 27.4 M |
| Equity | 64.44 M | 12.2 M | -24.68 M | -10.74 M |
| Current Assets | 89.89 M | 38.11 M | 10.66 M | 27.09 M |
| Current Liabilities | 6.64 M | 5.2 M | 10.62 M | 7.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -25.25 M | -25.31 M | -19.08 M | -16.02 M |
| Investing CF | 0 M | 0 M | 4.4 M | -0.02 M |
| Financing CF | 77.44 M | 52.61 M | 12 M | 14.75 M |
| Free CF | -25.25 M | -25.31 M | -19.08 M | -16.04 M |
| Capex | — | — | — | -0.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | -100% | — |
| Earnings Growth % | -46.11% | 8.83% | -5.67% | — |
| Profit Margin % | — | -1815.34% | — | -949.65% |
| Operating Margin % | — | -2377.58% | — | -1116.95% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -2213.96% | — | -1227.25% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-11-21 | 1:0.025 |